317 related articles for article (PubMed ID: 32066201)
21. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
Bala Tannan N; Manzari MT; Herviou L; Da Silva Ferreira M; Hagen C; Kiguchi H; Manova-Todorova K; Seshan V; de Stanchina E; Heller DA; Younes A
Blood; 2021 Apr; 137(15):2057-2069. PubMed ID: 33067607
[TBL] [Abstract][Full Text] [Related]
22. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
[TBL] [Abstract][Full Text] [Related]
23. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
25. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
[No Abstract] [Full Text] [Related]
27. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
[TBL] [Abstract][Full Text] [Related]
28. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
29. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
30. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
31. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
[TBL] [Abstract][Full Text] [Related]
32. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A; Szlavik Z; Murray J; Davidson J; Maragno AL; Le Toumelin-Braizat G; Chanrion M; Kelly GL; Gong JN; Moujalled DM; Bruno A; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Ondi L; Blasko G; Robertson A; Surgenor A; Dokurno P; Chen I; Matassova N; Smith J; Pedder C; Graham C; Studeny A; Lysiak-Auvity G; Girard AM; Gravé F; Segal D; Riffkin CD; Pomilio G; Galbraith LC; Aubrey BJ; Brennan MS; Herold MJ; Chang C; Guasconi G; Cauquil N; Melchiore F; Guigal-Stephan N; Lockhart B; Colland F; Hickman JA; Roberts AW; Huang DC; Wei AH; Strasser A; Lessene G; Geneste O
Nature; 2016 Oct; 538(7626):477-482. PubMed ID: 27760111
[TBL] [Abstract][Full Text] [Related]
33. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
34. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
[TBL] [Abstract][Full Text] [Related]
35. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
36. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P
Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569
[TBL] [Abstract][Full Text] [Related]
37. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
[TBL] [Abstract][Full Text] [Related]
39. Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
Freise KJ; Jones AK; Verdugo ME; Menon RM; Maciag PC; Salem AH
Clin Pharmacol Ther; 2017 Dec; 102(6):970-976. PubMed ID: 28419431
[TBL] [Abstract][Full Text] [Related]
40. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
AlZahrani A; Alsuhebany N; Tailor IK; Alrajhi AM
Hematology; 2024 Dec; 29(1):2296809. PubMed ID: 38149670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
